Dr. Daniel Ahn, PHYSICIAN
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 8
- In the NPI registry since
- 2018
- Medicare patients seen, 2024
- 80
Licensed in Texas since 2025, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
TX license V9451 (first issued 2025; active) · NJ license 25MB11111300
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Premier Endovascular, PLLC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 80
- Services billed
- 462
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Ultrasound study of arm or leg veins with compression and maneuvers | 66 | 58 |
| Established patient office or other outpatient visit, 10-19 minutes | 63 | 22 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 53 | 20 |
| New patient office or other outpatient visit, 30-44 minutes | 53 | 53 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 28 | 16 |
| Injection of chemical agent into single incompetent vein of leg using ultrasound guidance | 19 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 6 companies reported 11 payments worth $7,122 in total to this clinician.
| Angiodynamics, Inc. | $6,472 |
|---|---|
| Tactile Systems Technology Inc | $420 |
| Medtronic, Inc. | $162 |
| Dompe US, Inc. | $30.29 |
| Bausch & Lomb Americas Inc. | $19.12 |
| Glaukos Corporation | $18.51 |
| Long term medical supply or device loan | $6,472 |
|---|---|
| Food and Beverage | $650 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Angiodynamics, Inc. Dec 31, 2025 | Long term medical supply or device loan Auryon Laser System 100-120 Vac · CV · in-kind | $6,472 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $10,433 in research payments for these studies, mostly to the institutions running them.
- A Phase II study of Olaparib in patients with advanced biliary tract cancer expressing aberrant DNA repair
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.